Skip to main content
OpenTrials
Completed

NCT Number: NCT02273453

Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets

Study to determine the presence of a hang-over effect in healthy volunteers the day after the administration of Songha® Night

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female Caucasian subjects aged 20-60 years
  • Normal outcome in Pittsburgh Sleep Quality Index (PSQI), below mean +2 Standard Deviation (SDs)
  • No manifest sleep disorder diagnosed by polysomnography
  • Normal pupillary function
  • Willing and able to give written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to participation in the study and able to perform the study during the full time period of 36 days

Exclusion criteria

  • Subjective sleep duration of less than 3 hours in the night before the test
  • Caffeine, nicotine or alcohol on the day (from midnight) of the test
  • Alcohol consumption on the evening before visits 3, 5 or 7
  • Eye-drops or other drugs, taken orally or intravenously, influencing pupil size or motility
  • Shift work
  • Drug and alcohol abuse
  • Use of psycho-active drugs during the past 30 days
  • Any treatment that might interfere with the evaluation of the test drug
  • Any drug known to interact with benzodiazepines and related drugs, e.g. antiepileptics, antihistaminics, muscle relaxant drugs, antihypertensive drugs, drugs inhibiting cytochrome P450
  • Any serious disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
  • Known hypersensitivity to any of the ingredients of the study drugs
  • Pregnant or nursing women or inadequate birth control methods (this applies to female of childbearing potential only)
  • Participation in another trial within the past 30 days

Treatment and study plan

Songha® Night

Drug

Oxazepam

Drug

Placebo

Drug

Primary outcomes

  1. Changes from baseline of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test

    Time frame: 08:00h, 09:30h, 11:00h at Day 7 of each treament period

Secondary outcomes

  1. Change of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test

    Time frame: up to day 36

  2. Change in subjective sleepiness rated on a 7 point scale

    Time frame: up to day 36

    Stanford Sleepiness Scale

  3. Change in subjective sleepiness measured on a visual analogue scale (VAS)

    Time frame: up to day 36

  4. Change in sleep quality measured on a visual analogue scale (VAS)

    Time frame: up to day 36

  5. Global Assessment of tolerability by investigator on 4-point scale

    Time frame: Day 36

  6. Global Assessment of tolerability by patient on 4-point scale

    Time frame: Day 36

  7. Number of subjects with adverse events

    Time frame: up to 36 days

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm)

Important dates

Study start
2003
Primary completion
2003
First posted
Oct 24, 2014
Registry last updated
Oct 24, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.